Maximizing value in early phase oncology trials through innovative endpoint strategies

Advanced imaging endpoints enable earlier insight into biological response

Traditional radiologic assessments may lack the sensitivity needed to detect subtle biological changes in early phase oncology studies. Advanced imaging endpoints provide a more quantitative and dynamic understanding of treatment response earlier in development.

AI-supported imaging with expert oversight

AI-supported lesion segmentation enables the generation of high value imaging biomarkers, such as total tumor burden. This approach improves consistency and scalability across studies, while expert human oversight remains essential to ensure clinical relevance and data integrity.

When paired with advanced analytical techniques, including tumor growth kinetics, imaging endpoints allow teams to move beyond static RECIST assessments and gain earlier insight into treatment effects.

Strategic value includes:

• Earlier detection of biological response signals
• Improved confidence in dose escalation and selection decisions
• More informative early go or no-go assessments

Early cardiac safety modeling reduces risk with minimal additional operational complexity

Cardiac safety remains a critical consideration in oncology development, particularly when therapies have potential or known cardiotoxic effects. In early phase oncology trials, where healthy volunteers and placebo comparators are typically not included, advanced cardiac safety modeling becomes essential.

Concentration effect modeling for proactive assessment

By integrating pharmacokinetic data with cardiac safety measurements, concentration effect modeling enables quantitative assessment of cardiac risk with minimal added cost or operational burden.

This approach supports earlier identification of potential safety signals while maintaining efficient study design.

Key benefits include:

• Faster transition from first in human and dose escalation studies into Phase II and Phase III
• More informed dose selection supported by quantitative safety evidence
• More streamlined regulatory interactions through demonstrated safety diligence
• Reduced downstream risk through earlier identification of cardiotoxicity concerns

Integrating PROs strengthens patient centered development

Regulatory guidance emphasizes the importance of incorporating the patient’s perspective early in clinical development. Electronic Patient-Reported Outcomes (ePROs) provide near real-time insight into tolerability, symptom burden and symptomatic adverse events that are often under reported through clinician assessments alone.

Value of PROs in early phase oncology

Including PROs in early phase strategy helps sponsors:

• Enhance patient safety monitoring
• Build a more comprehensive risk-benefit profile
• Inform dose selection and tolerability thresholds
• Capture patient impact including key symptoms often missed by clinicians
• Align early evidence with evolving regulatory expectations for patient centered data

Delivering greater strategic value from early phase oncology trials

When advanced imaging, cardiac safety modeling and PROs are integrated, early phase oncology trials become more than safety checkpoints. They serve as engines for informed decision-making across development programs.

Concentration effect modeling for proactive assessment

By integrating pharmacokinetic data with cardiac safety measurements, concentration effect modeling enables quantitative assessment of cardiac risk with minimal added cost or operational burden.

Integrated endpoint strategies support:

• Earlier, evidence-based go or no-go decisions
• Greater confidence in Phase II dose selection
• Improved alignment with regulatory and patient expectations
• Higher quality, decision ready clinical evidence